Fullcircle Wealth LLC Purchases 80 Shares of AbbVie Inc. (NYSE:ABBV)

Fullcircle Wealth LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,518 shares of the company’s stock after buying an additional 80 shares during the period. Fullcircle Wealth LLC’s holdings in AbbVie were worth $1,254,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. EnRich Financial Partners LLC increased its position in AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after buying an additional 110 shares during the period. Prudent Man Investment Management Inc. acquired a new position in shares of AbbVie in the fourth quarter valued at about $32,000. Siemens Fonds Invest GmbH increased its position in AbbVie by 197.6% during the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company’s stock worth $32,000 after acquiring an additional 119,141 shares during the period. Pinney & Scofield Inc. acquired a new stake in AbbVie in the 4th quarter worth about $36,000. Finally, Redwood Park Advisors LLC bought a new stake in AbbVie in the 4th quarter valued at about $40,000. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

ABBV has been the topic of several recent research reports. Guggenheim raised their target price on shares of AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Bank of America raised their price target on AbbVie to $204.00 and gave the stock a “hold” rating in a research report on Monday, June 9th. Citigroup increased their price target on shares of AbbVie to $205.00 and gave the stock a “hold” rating in a research report on Wednesday, June 11th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Finally, Evercore ISI lifted their target price on AbbVie from $204.00 to $205.00 and gave the company an “outperform” rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Price Performance

AbbVie stock opened at $189.50 on Monday. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $218.66. The company’s 50 day moving average price is $187.37 and its two-hundred day moving average price is $188.68. The stock has a market cap of $334.73 billion, a P/E ratio of 80.64, a P/E/G ratio of 1.26 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.40 by $0.06. The business had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. AbbVie’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company posted $2.31 earnings per share. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.46%. The ex-dividend date is Tuesday, July 15th. AbbVie’s dividend payout ratio is 279.15%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.